[
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
[og_img]
https://www.investing.com/news/press-releases/madrigal-announces-new-clinical-data-demonstrating-rezdiffra-resmetirom-significantly-improved-multiple-noninvasive-tests-and-portal-hypertension-risk-in-patients-with-compensated-mash-cirrhosis-93CH-4037691
Investing.com
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Related articles